I hold a small position in XXII.
I like their FDA contracts and interactions, and I also like the genetically "favored" cannabis horticulture for natural products extractions, amongst other things.
I do not usually invest in reefer stocks, but this one really is technology driven and lots of things going on. Also, XXII is a press release machine, a behavior that could be bothersome. Or not.
Could be a ten-bagger, or a bust.